The prevalence of fatigue among patients with chronic obstructive pulmonary disease (COPD) worldwide is approximately 59%, according to systematic review and meta-analysis findings published in ...
The Prescription Drug User Fee Act (PDUFA) date refers to the deadline set by the US Food and Drug Administration (FDA) for reviewing a New Drug Application (NDA) or Biologics License Application (BLA ...
The Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for depemokimab for asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback